Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) earlier this week announced the publication of its preclinical cancer therapy study in Frontiers in Immunology.
The company explained that its patented gold nanorod technology is at the center of Targeted Hyperthermia Therapy (THT), an innovative approach that destroys tumors using laser-induced heat.
Sona said the gold nanorods are injected directly into tumors, where a laser activates them to generate heat.
David Regan, CEO of Sona Nanotech, emphasized that this process minimizes collateral damage and addresses key concerns about toxicity. "Our patented, uniquely biocompatible gold nanorods don't contain toxins," he noted.
Regan said the company plans to begin human trials this year, targeting late-stage melanoma patients who have exhausted other treatment options. The preclinical data suggests that THT can act as a catalyst, enhancing the effectiveness of immunotherapy to eliminate tumors.
To support regulatory submissions in Canada and the US, Sona Nanotech is working with third-party labs to conduct comprehensive safety studies.
Regan highlighted the company’s focus on data collection as it moves toward larger clinical studies in 2026.